progression-free survival
Figure 2 · Panel A
Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Luca Bertamini, Cathelijne Fokkema, Paula Rodriguez-Otero, Mark van Duin, Evangelos Terpos, Mattia D'Agostino, Vincent H J van der Velden, Niels W C J van de Donk, Michel Delforge, Christoph Driessen, Roman Hajek, Hermann Einsele, Annette Vangsted, Diego Vieyra, Ricardo Attar, Anna Sitthi-Amorn, Robin Carson, Fredrik Schjesvold, Pawel Robak, Meral Beksac, Andrew Spencer, Annemiek Broijl, Tom Cupedo, Philippe Moreau, Mario Boccadoro, Pieter Sonneveld
Blood 147(4) 431-442
Circulating tumor cells (CTC) represent a high-risk biomarker in newly diagnosed multiple myeloma (NDMM); however, their prognostic value among transplant-eligible (TE) patients receiving daratumumab/bortezomib/lenalidomide/dexamethasone (D-VRd) remains unknown. In this study, we analyzed CTC in the phase 3 PERSEUS/EMN017 trial. TE-NDMM patients were randomized (1:1) to D-VRd with daratumumab/lenalidomide maintenance (D-VRd group) or bortezomib/lenalidomide/dexamethasone (VRd) with lenalidomide maintenance (VRd group), both with transplant. A subset of 451 of 709 patients from PERSEUS (D-VRd, 231/355; VRd, 220/354) had screening blood samples collected for CTC analysis by flow cytometry. CTC were detected in 370 patients (82%; median limit of detection, 0.0004%). CTC were prognostic of progression-free survival (PFS), independent of other factors, as a continuous (hazard ratio [HR], 1.36 [95% confidence interval (CI), 1.15-1.60]; P< .001) and categorical variable (≥0.175% CTC-high, optimal threshold). D-VRd improved PFS vs VRd in CTC-low patients (4-year rates: 88% vs 74%; HR, 0.42 [95% CI, 0.25-0.70]; P = .0013). Regardless of study treatment, minimal residual disease (MRD)-negativity rates were lower in CTC-high vs CTC-low patients (10-5: 52.2% vs 66.2%; 10-6: 34.8% vs 52.4%). D-VRd significantly increased MRD-negativity rates vs VRd among CTC-high (10-5: 69.4% vs 33.3%; 10-6: 47.2% vs 21.2%; both P< .05) and CTC-low patients (10-5: 74.4% vs 57.8%; 10-6: 65.6% vs 38.5%; both P< .001), with similar observations for sustained MRD-negativity. CTC levels are an independent prognostic factor in TE-NDMM treated with standard-of-care frontline quadruplet. D-VRd improved and sustained MRD-negativity rates in CTC-high and CTC-low, and improved PFS for CTC-low with a positive trend in CTC-high patients. This trial was registered at www.clinicaltrials.gov as #NCT03710603.
3 个 Figure · 5 个 KM 面板
Figure 2. Prognostic impact of varying CTC levels and its independence of other risk factors. (A) Estimated PFS is progressively inferior in patients with increasing (log 10 ) levels of CTC. (B) Cox regression model including other well established risk factors (ISS, cytogenetics, and LDH) and treatment shows independent prognostic impact of increasing CTC levels (continuous variable). a Comparison with standard-risk. High-risk cytogenetics is defined by the presence of del(17p), t(4;14), and/or t(14;16) by fluorescence in situ hybridization. Absence of those is considered standard-risk.
Figure 2 · Panel A
Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3. Prognostic impact of CTC levels (high vs low) with optimal threshold and treatment. (A) Elevated CTC (CTC-high) with an optimal threshold (0.175%) show impact on PFS in the study population (n = 451). (B) Impact of CTC levels and treatment in PERSEUS study, where treatment with D-VRd improved outcomes in CTC-low patients but did not fully overcome the high risk portended by CTC-high. CTC-high is defined by CTC ≥0.175%; CTC-low is defined by CTC <0.175%.
Figure 5. MRD modulates the impact of CTC levels at diagnosis. (A) Landmark analysis (12 months from start of therapy) of PFS outcomes shows how achievement of MRD negativity (10 –6 threshold) modulates outcome of patients stratified by CTC levels at diagnosis. (B) Landmark analysis (24 months from start of therapy) shows similar PFS outcomes in patients with sustained (≥12 months) MRD negativity (10 –6 threshold) regardless of their CTC levels. CTC-high is defined by CTC ≥0.175%; CTC-low is defined by CTC <0.175%.
这些图片未产生 KM 曲线结果,不在主页面重复展示。